Citations (108)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Jiali Xie, Xiaoxuan Zhang, Dan Meng, Yihao Li & Ping Deng. (2023) Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-19.
Read now
Read now
Cilong Chu, Zixuan Rao, Qingshan Pan & Wufu Zhu. (2022) An updated patent review of small-molecule c-Met kinase inhibitors (2018-present). Expert Opinion on Therapeutic Patents 32:3, pages 279-298.
Read now
Read now
Simon Vyse & Paul H Huang. (2022) Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. Expert Review of Anticancer Therapy 22:1, pages 3-16.
Read now
Read now
Ryo Fujita, Vincent Blot, Eley Wong, Christine Stewart, Vincent Lieuw, Robyn Richardson, Ammar Banah, Jose Villicana, Anjuli Timmer, Julia Coronella, Roland Newman & Marco Gymnopoulos. (2020) A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers. Cancer Biology & Therapy 21:6, pages 549-559.
Read now
Read now
Hong-Qing Zhuang, Qi-Fu Bo, Zhi-Yong Yuan, Jun Wang, Lu-Jun Zhao & Ping Wang. (2013) The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction. OncoTargets and Therapy 6, pages 603-608.
Read now
Read now
Bianca M. Liederer, Xingrong Liu, Leonid M. Berezhkovskiy, Gary Cain, Xiao Ding, John Gaudino, Robert Kaus, Emile G. Plise, Daniel P. Sutherlin & Eric B. Harstad. (2012) Preclinical stereoselective disposition and toxicokinetics of two novel MET inhibitors. Xenobiotica 42:5, pages 456-465.
Read now
Read now
Andreas Varkaris, Paul G Corn, Sanchaika Gaur, Farshid Dayyani, Christopher J Logothetis & Gary E Gallick. (2011) The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opinion on Investigational Drugs 20:12, pages 1677-1684.
Read now
Read now
Xiangdong Liu, Robert C Newton & Peggy A Scherle. (2011) Development of c-MET pathway inhibitors. Expert Opinion on Investigational Drugs 20:9, pages 1225-1241.
Read now
Read now
Bianca M. Liederer, Leonid M. Berezhkovskiy, Brian J. Dean, Vikki Dinkel, Jing Peng, Mark Merchant, Emile G. Plise, Harvey Wong & Xingrong Liu. (2011) Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic–pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor. Xenobiotica 41:4, pages 327-339.
Read now
Read now
John Porter. (2010) Small molecule c-Met kinase inhibitors: a review of recent patents. Expert Opinion on Therapeutic Patents 20:2, pages 159-177.
Read now
Read now
Articles from other publishers (98)
Rakesh Sahu, Kamal Shah, Yash Gautam & Kaushilya Sahu. (2023) Pyrazine Moiety: Recent Developments in Cancer Treatment. Current Organic Chemistry 27:10, pages 821-843.
Crossref
Crossref
Eleonora Orlando, Matúš Medo, Ariel Bensimon, Aurélie Quintin, Rahel Riedo, Selina M. Roth, Carsten Riether, Thomas M. Marti, Daniel M. Aebersold, Michaela Medová, Ruedi Aebersold & Yitzhak Zimmer. (2022) An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. Cellular and Molecular Life Sciences 80:1.
Crossref
Crossref
Jingyue Kang, Tonglin Sun & Yan Zhang. (2022) Immunotherapeutic progress and application of bispecific antibody in cancer. Frontiers in Immunology 13.
Crossref
Crossref
Kai Cai, Xuewu Zhang & Xiao-chen Bai. (2022) Cryo-electron Microscopic Analysis of Single-Pass Transmembrane Receptors. Chemical Reviews 122:17, pages 13952-13988.
Crossref
Crossref
Sima Biswas & Angshuman Bagchi. 2022. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects
3215
3227
.
Sima Biswas & Angshuman Bagchi. 2021. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects
1
14
.
Zhiyuan Jiang, Zhaolun Cai, Qin Ma, Chaoyong Shen, Yuan Yin, Xiaonan Yin, Chunyu Liu, Chen Chang, Zhou Zhao, Mingchun Mu & Bo Zhang. (2021) Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis. BMJ Open 11:12, pages e049575.
Crossref
Crossref
Kevin B. Elmore & Lauren R. Schaff. (2021) DNA Repair Mechanisms and Therapeutic Targets in Glioma. Current Oncology Reports 23:8.
Crossref
Crossref
Enrique Grande, Monica Giovannini, Eddie Marriere, Philippe Pultar, Michelle Quinlan, Xinhui Chen, Gholamreza Rahmanzadeh, Giuseppe Curigliano & Xiaoming Cui. (2020)
Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2‐drug cocktail in patients with
MET
‐dysregulated advanced solid tumours: A phase I, multicentre, open‐label, single‐sequence drug–drug interaction study
. British Journal of Clinical Pharmacology 87:7, pages 2867-2878.
Crossref
Crossref
Yuting Guo, Xia Peng, Yinchun Ji, Yitong Zhang, Jian Ding, Zhengsheng Zhan, Jing Ai & Wenhu Duan. (2020) Synthesis of triazolotriazine derivatives as c-Met inhibitors. Molecular Diversity 25:2, pages 839-846.
Crossref
Crossref
Joost Neijssen, Rosa M.F. Cardoso, Kristen M. Chevalier, Luus Wiegman, Thomas Valerius, G. Mark Anderson, Sheri L. Moores, Janine Schuurman, Paul W.H.I. Parren, William R. Strohl & Mark L. Chiu. (2021) Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. Journal of Biological Chemistry 296, pages 100641.
Crossref
Crossref
Yuting Zhou, Xingwei Xu, Fei Wang, Huan He & Baohui Qi. (2021) Discovery of 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-methoxyquinolin-7-yl)oxy)-N,N-diethylpiperidine-1-carboxamide as kinase inhibitor for the treatment of colorectal cancer. Bioorganic Chemistry 106, pages 104511.
Crossref
Crossref
Wenqiang Cui, Adnane Aouidate, Shouguo Wang, Qiuliyang Yu, Yanhua Li & Shuguang Yuan. (2020) Discovering Anti-Cancer Drugs via Computational Methods. Frontiers in Pharmacology 11.
Crossref
Crossref
Eman M. Ahmed, Nadia A. Khalil, Azza T. Taher, Rana H. Refaey & Yassin M. Nissan. (2019) Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking. Bioorganic Chemistry 92, pages 103272.
Crossref
Crossref
Yanhua Fan, Huaiwei Ding, Donghwa Kim, Duc-Hiep Bach, Ji-Young Hong, Yongnan Xu & Sang Kook Lee. (2019) Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer. Cancers 11:5, pages 627.
Crossref
Crossref
Eleonora Orlando, Daniel Matthias Aebersold, Michaela Medová & Yitzhak Zimmer. (2019) Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. Cancer Letters 443, pages 189-202.
Crossref
Crossref
Zhengsheng Zhan, Xia Peng, Yiming Sun, Jing Ai & Wenhu Duan. (2018)
Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and
in Vivo
Antitumor Profiles
. Chemical Research in Toxicology 31:11, pages 1213-1218.
Crossref
Crossref
Wei Shi, Hao Qiang, Dandan Huang, Xinzhou Bi, Wenlong Huang & Hai Qian. (2018) Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2. European Journal of Medicinal Chemistry 158, pages 814-831.
Crossref
Crossref
Astrid A. Glück, Eleonora Orlando, Dominic Leiser, Michaela Poliaková, Lluís Nisa, Aurélie Quintin, Jacopo Gavini, Deborah M. Stroka, Sabina Berezowska, Lukas Bubendorf, Andree Blaukat, Daniel M. Aebersold, Michaela Medová & Yitzhak Zimmer. (2018) Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia. Oncogene 37:30, pages 4181-4196.
Crossref
Crossref
Leonardi Leonardo, Pazzaglia Laura & Benassi Maria Serena. (2018) miR-1 and miR-133b expression in canine osteosarcoma. Research in Veterinary Science 117, pages 133-137.
Crossref
Crossref
Zhaoguo Han, Yongyi Wu, Kai Wang, Yadi Xiao, Zhen Cheng, Xilin Sun & Baozhong Shen. (2017) Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review. EJNMMI Research 7:1.
Crossref
Crossref
Mehrdad Pazhouhandeh, Fatemeh Samiee, Tahereh Boniadi, Abbas Fadaei Khedmat, Ensieh Vahedi, Mahsa Mirdamadi, Naseh Sigari, Seyed Davar Siadat, Farzam Vaziri, Abolfazl Fateh, Faezeh Ajorloo, Elham Tafsiri, Mostafa Ghanei, Fereidoun Mahboudi & Fatemeh Rahimi Jamnani. (2017) Comparative Network Analysis of Patients with Non-Small Cell Lung Cancer and Smokers for Representing Potential Therapeutic Targets. Scientific Reports 7:1.
Crossref
Crossref
Yanmei Zhao, Jiankang Zhang, Rangxiao Zhuang, Ruoyu He, Jianjun Xi, Xuwang Pan, Yidan Shao, Jinming Pan, Jingjing Sun, Zhaobin Cai, Shourong Liu, Weiwei Huang & Xiaoqing Lv. (2017) Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors. Bioorganic & Medicinal Chemistry 25:12, pages 3195-3205.
Crossref
Crossref
Wei Deying, Geng Feng, Liang Shumei, Zhao Hui, Liu Ming & Wang Hongqing. (2017) CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells. Bioscience Reports 37:2.
Crossref
Crossref
Johanna C. Bendell, Howard Hochster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace, Joshua J. McFarlane, Mark Kozloff, Daniel Catenacci, Jessie J. Hsu, Stephen P. Hack, David S. Shames, See-Chun Phan, Hartmut Koeppen & Allen L. Cohn. (2017) A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. The Oncologist 22:3, pages 264-271.
Crossref
Crossref
In-Ho Kim, In Hee Lee, Ji Eun Lee, Sook Hee Hong, Tae-Jung Kim, Kyo-Young Lee, Young Kyoon Kim, Seung Joon Kim, Sook Whan Sung, Jae Kil Park, Ie Ryung Yoo, Yeon Sil Kim, Jung-Oh Kim & Jin Hyoung Kang. (2016) Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma. Annals of Surgical Oncology 24:3, pages 770-777.
Crossref
Crossref
Jun PeiTianqing ChuMinhua ShaoJiajun TengHuifang ShaAiqing GuRong LiJialin QianWeifeng MaoYing LiBaohui Han. (2017) Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells. Yonsei Medical Journal 58:3, pages 581.
Crossref
Crossref
Hongqing Zhuang, Jing Bai, Joe Y. Chang, Zhiyong Yuan & Ping Wang. (2016) MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget 7:51, pages 84688-84694.
Crossref
Crossref
L Zhu, X Cheng, J Shi, J Lin, G Chen, H Jin, A B Liu, H Pyo, J Ye, Y Zhu, H Wang, H Chen, J Fang, L Cai, T C Wang, C S Yang & S P Tu. (2016) Crosstalk between bone marrow-derived myofibroblasts and gastric cancer cells regulates cancer stemness and promotes tumorigenesis. Oncogene 35:41, pages 5388-5399.
Crossref
Crossref
Mingmei Liu, Yunlei Hou, Weile Yin, Shunguang Zhou, Ping Qian, Zhuang Guo, Liying Xu & Yangfang Zhao. (2016) Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors. European Journal of Medicinal Chemistry 119, pages 96-108.
Crossref
Crossref
Ying Wang, Zhengsheng Zhan, Xifei Jiang, Xia Peng, Yanyan Shen, Fang Chen, Yinchun Ji, Weiren Liu, Yinghong Shi, Wenhu Duan, Jian Ding, Jing Ai & Meiyu Geng. (2016) Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities. Oncotarget 7:25, pages 38091-38104.
Crossref
Crossref
Zhengsheng Zhan, Xia Peng, Qiufeng Liu, Fang Chen, Yinchun Ji, Shanyan Yao, Yong Xi, Yipeng Lin, Tiantian Chen, Yechun Xu, Jing Ai, Meiyu Geng & Wenhu Duan. (2016) Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3- b ][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor. European Journal of Medicinal Chemistry 116, pages 239-251.
Crossref
Crossref
Pei‐Pei Kung, Ricky Anthony Jones & Paul Richardson. 2015. Innovative Drug Synthesis. Innovative Drug Synthesis
119
156
.
Lan Zhao, Yan Wu, Xu-Dong Xie, Yi-Fan Chu, Jin-Qing Li & Limin Zheng. (2015) c-Met identifies a population of matrix metalloproteinase 9-producing monocytes in peritumoural stroma of hepatocellular carcinoma. The Journal of Pathology 237:3, pages 319-329.
Crossref
Crossref
Wasia Rizwani, Amanda Allen & Jose Trevino. (2015) Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge. Cancers 7:3, pages 1785-1805.
Crossref
Crossref
Lunhui Zhang, Ping Ju, Feifei Zhou, Yuanyuan Zhang, Simin Zhao, Yu Jiang, Kaishun Bi & Xiaohui Chen. (2015) The absolute bioavailability investigation of LS177 in rats using ultra-performance liquid chromatography-tandem mass spectrometry. Drug Testing and Analysis 7:9, pages 756-762.
Crossref
Crossref
Y-M Cui, H-L Jiao, Y-P Ye, C-M Chen, J-X Wang, N Tang, T-T Li, J Lin, L Qi, P Wu, S-Y Wang, M-R He, L Liang, X-W Bian, W-T Liao & Y-Q Ding. (2014) RETRACTED ARTICLE: FOXC2 promotes colorectal cancer metastasis by directly targeting MET. Oncogene 34:33, pages 4379-4390.
Crossref
Crossref
Emily A. Peterson, Yohannes Teffera, Brian K. Albrecht, David Bauer, Steven F. Bellon, Alessandro Boezio, Christiane Boezio, Martin A. Broome, Deborah Choquette, Katrina W. Copeland, Isabelle Dussault, Richard Lewis, Min-Hwa Jasmine Lin, Julia Lohman, Jingzhou Liu, Michele Potashman, Karen Rex, Roman Shimanovich, Douglas A. Whittington, Karina R. Vaida & Jean-Christophe Harmange. (2015) Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors. Journal of Medicinal Chemistry 58:5, pages 2417-2430.
Crossref
Crossref
Yuji Sano, Eri Hashimoto, Noriaki Nakatani, Masaichi Abe, Yasuko Satoh, Kiyoaki Sakata, Toshihiko Fujii, Kaori Fujimoto-Ouchi, Masamichi Sugimoto, Shigehisa Nagahashi, Masahiro Aoki, Hiroshi Motegi, Eiichi Sasaki & Yasushi Yatabe. (2015)
Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating
EGFR
Mutations and HGF Overexpression
. Molecular Cancer Therapeutics 14:2, pages 533-541.
Crossref
Crossref
Xiaolong Jiang, Hongyan Liu, Zilan Song, Xia Peng, Yinchun Ji, Qizheng Yao, Meiyu Geng, Jing Ai & Ao Zhang. (2015) Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold. Bioorganic & Medicinal Chemistry 23:3, pages 564-578.
Crossref
Crossref
Paul W Sylvester. (2014) Targeting met mediated epithelial‐mesenchymal transition in the treatment of breast cancer. Clinical and Translational Medicine 3:1.
Crossref
Crossref
Hong-Qing Zhuang, Hongxia Zhuang, Qifu Bo, Yihang Guo, Jun Wang, Lu-Jun Zhao, Zhi-Yong Yuan & Ping Wang. (2014) Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody. Cancer Cell International 14:1.
Crossref
Crossref
Júlia L.F. Abrantes, Thaís F. Tornatore, Karin J. Pelizzaro-Rocha, Marcelo B. de Jesus, Rodrigo T. Cartaxo, Renato Milani & Carmen V. Ferreira-Halder. (2014) Crosstalk between kinases, phosphatases and miRNAs in cancer. Biochimie 107, pages 167-187.
Crossref
Crossref
Seung-Tae Kang, Eun-Young Kim, Raghavendra Archary, Heejung Jung, Chi Hoon Park, Chang-Soo Yun, Jong Yeon Hwang, Sang Un Choi, Chonghak Chae, Chong Ock Lee, Hyoung Rae Kim, Jae Du Ha, Dohyun Ryu & Sung Yun Cho. (2014) Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 24:21, pages 5093-5097.
Crossref
Crossref
Lu Wang, Jing Ai, Yanyan Shen, Haotian Zhang, Xia Peng, Min Huang, Ao Zhang, Jian Ding & Meiyu Geng. (2014) SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo. Cancer Letters 351:1, pages 143-150.
Crossref
Crossref
Daniel V. T. Catenacci, Wei-Li Liao, Sheeno Thyparambil, Les Henderson, Peng Xu, Lei Zhao, Brittany Rambo, John Hart, Shu-Yuan Xiao, Kathleen Bengali, Jamar Uzzell, Marlene Darfler, David B. Krizman, Fabiola Cecchi, Donald P. Bottaro, Theodore Karrison, Timothy D. Veenstra, Todd Hembrough & Jon Burrows. (2014) Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue. PLoS ONE 9:7, pages e100586.
Crossref
Crossref
Zijian Liu, Rui Wang, Ruiming Guo, Jinxing Hu, Ruijuan Li, Yanfang Zhao & Ping Gong. (2014) Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry 22:14, pages 3642-3653.
Crossref
Crossref
Qidong Tang, Guogang Zhang, Xinming Du, Wufu Zhu, Ruijuan Li, Huafang Lin, Pengcheng Li, Maosheng Cheng, Ping Gong & Yanfang Zhao. (2014) Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry 22:4, pages 1236-1249.
Crossref
Crossref
Oliver Surriga, Vinagolu K. Rajasekhar, Grazia Ambrosini, Yildrim Dogan, Ruimin Huang & Gary K. Schwartz. (2013) Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model. Molecular Cancer Therapeutics 12:12, pages 2817-2826.
Crossref
Crossref
Zhe Yu, Yu-chi Ma, Jing Ai, Dan-qi Chen, Dong-mei Zhao, Xin Wang, Yue-lei Chen, Mei-yu Geng, Bing Xiong, Mao-sheng Cheng & Jing-kang Shen. (2013) Energetic factors determining the binding of type I inhibitors to c-Met kinase: experimental studies and quantum mechanical calculations. Acta Pharmacologica Sinica 34:11, pages 1475-1483.
Crossref
Crossref
Wenjuan Wu, Chen Bi, Kelly M. Credille, Jason R. Manro, Victoria L. Peek, Gregory P. Donoho, Lei Yan, John A. Wijsman, S. Betty Yan & Richard A. Walgren. (2013) Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET. Clinical Cancer Research 19:20, pages 5699-5710.
Crossref
Crossref
Sang-Won Hong, Kyung Hee Jung, Hee-Seung Lee, Mi Kwon Son, Hong Hua Yan, Nam Sook Kang, Jongkook Lee & Soon-Sun Hong. (2013) SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities. Carcinogenesis 34:9, pages 2156-2169.
Crossref
Crossref
Rahul Ingle, Rajendra Marathe, Dipak Magar, Harun M. Patel & Sanjay J. Surana. (2013) Sulphonamido-quinoxalines: Search for anticancer agent. European Journal of Medicinal Chemistry 65, pages 168-186.
Crossref
Crossref
Byung Hee Park, Kyung Hee Jung, Sun-Mi Yun, Sang-Won Hong, Jae Wook Ryu, Heejung Jung, Jae Du Ha, Jongkook Lee & Soon-Sun Hong. (2013) KRC-327, a selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity. Cancer Letters 331:2, pages 158-166.
Crossref
Crossref
Shunsuke Kondo, Hidenori Ojima, Hitoshi Tsuda, Jun Hashimoto, Chigusa Morizane, Masafumi Ikeda, Hideki Ueno, Kenji Tamura, Kazuaki Shimada, Yae Kanai & Takuji Okusaka. (2012) Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. International Journal of Clinical Oncology 18:2, pages 207-213.
Crossref
Crossref
Chonglin Luo, Paul W. Tetteh, Patrick R. Merz, Elke Dickes, Alia Abukiwan, Agnes Hotz-Wagenblatt, Stefan Holland-Cunz, Tobias Sinnberg, Birgit Schittek, Dirk Schadendorf, Sven Diederichs & Stefan B. Eichmüller. (2013) miR-137 Inhibits the Invasion of Melanoma Cells through Downregulation of Multiple Oncogenic Target Genes. Journal of Investigative Dermatology 133:3, pages 768-775.
Crossref
Crossref
Yong Wang, Zhong-Liang Xu, Jing Ai, Xia Peng, Jian-Ping Lin, Yin-Chun Ji, Mei-Yu Geng & Ya-Qiu Long. (2013) Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors. Org. Biomol. Chem. 11:9, pages 1545-1562.
Crossref
Crossref
Asish K. Ghosh & Neil E. Kay. 2013. Advances in Chronic Lymphocytic Leukemia. Advances in Chronic Lymphocytic Leukemia
215
239
.
Kanwal Pratap Singh Raghav & Cathy Eng. (2012) Role of the MET–HGF axis in colorectal cancer: precepts and prospects. Colorectal Cancer 1:4, pages 329-341.
Crossref
Crossref
Tove Reinertsen, Jostein Halgunset, Trond Viset, Arnar Flatberg, Linn Lervik Haugsmoen & Haakon Skogseth. (2012) Gene expressional changes in prostate fibroblasts from cancerous tissue. APMIS 120:7, pages 558-571.
Crossref
Crossref
Jongkook Lee, Sun-Young Han, Heejung Jung, Jeon Yang, Jie-Won Choi, Chong Hack Chae, Chi Hoon Park, Sang Un Choi, Kwangho Lee, Jae Du Ha, Chong Ock Lee, Jae Wook Ryu, Hyoung Rae Kim, Jong Sung Koh & Sung Yun Cho. (2012) Synthesis and structure–activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 22:12, pages 4044-4048.
Crossref
Crossref
Kanwal P. Raghav, Wenting Wang, Shuying Liu, Mariana Chavez-MacGregor, Xiaolong Meng, Gabriel N. Hortobagyi, Gordon B. Mills, Funda Meric-Bernstam, George R. BlumenscheinJrJr & Ana M. Gonzalez-Angulo. (2012) cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes. Clinical Cancer Research 18:8, pages 2269-2277.
Crossref
Crossref
Jing Shi, Demao Yao, Wei Liu, Na Wang, Hongjun Lv, Nongyue He, Bingyin Shi, Peng Hou & Meiju Ji. (2012) Frequent Gene Amplification Predicts Poor Prognosis in Gastric Cancer. International Journal of Molecular Sciences 13:4, pages 4714-4726.
Crossref
Crossref
Jorrit J. Hornberg. 2012. Designing Multi-Target Drugs. Designing Multi-Target Drugs
1
13
.
B Cheng, C Ling, Y Dai, Y Lu, L G Glushakova, S W Y Gee, K E McGoogan, G V Aslanidi, M Park, P W Stacpoole, D Siemann, C Liu, A Srivastava & C Ling. (2011) Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Therapy 19:4, pages 375-384.
Crossref
Crossref
Kyung Hee Jung, Byung Hee Park & Soon-Sun Hong. (2012) Progress in cancer therapy targeting c-Met signaling pathway. Archives of Pharmacal Research 35:4, pages 595-604.
Crossref
Crossref
Shawna Leslie Organ, J Rafael Sierra & Ming-Sound Tsao. (2012) Therapeutic potential of c-MET inhibitors: background and clinical data. Clinical Investigation 2:3, pages 301-315.
Crossref
Crossref
Leen H. Kawas, Alene T. McCoy, Brent J. Yamamoto, John W. Wright & Joseph W. Harding. (2012) Development of Angiotensin IV Analogs as Hepatocyte Growth Factor/Met Modifiers. Journal of Pharmacology and Experimental Therapeutics 340:3, pages 539-548.
Crossref
Crossref
Gary E Gallick, Paul G Corn, Amado J Zurita & Sue-Hwa Lin. (2012) Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Medicinal Chemistry 4:1, pages 107-119.
Crossref
Crossref
B Taylor-Harding, H Agadjanian, H Nassanian, S Kwon, X Guo, C Miller, B Y Karlan, S Orsulic & C S Walsh. (2011) Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment. British Journal of Cancer 106:2, pages 333-343.
Crossref
Crossref
Jinxuan Hou, Jixin Dong, Lijun Sun, Liying Geng, Jing Wang, Jialin Zheng, Yan Li, Julia Bridge, Steven H Hinrichs & Shi-Jian Ding. (2011) Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. Journal of Translational Medicine 9:1.
Crossref
Crossref
N. M. Ayoub, S. V. Bachawal & P. W. Sylvester. (2011) γ-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells. Cell Proliferation 44:6, pages 516-526.
Crossref
Crossref
Xiangdong Liu, Qian Wang, Gengjie Yang, Cindy Marando, Holly K. Koblish, Leslie M. Hall, Jordan S. Fridman, Elham Behshad, Richard Wynn, Yu Li, Jason Boer, Sharon Diamond, Chunhong He, Meizhong Xu, Jincong Zhuo, Wenqing Yao, Robert C. Newton & Peggy A. Scherle. (2011) A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3. Clinical Cancer Research 17:22, pages 7127-7138.
Crossref
Crossref
Johann S. de Bono & Timothy A. Yap. (2011) Future directions in the evaluation of c-MET-driven malignancies. Therapeutic Advances in Medical Oncology 3:1_suppl, pages S51-S60.
Crossref
Crossref
Neelesh Sharma & Alex A. Adjei. (2011) In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs. Therapeutic Advances in Medical Oncology 3:1_suppl, pages S37-S50.
Crossref
Crossref
Johann S. de Bono & Timothy A. Yap. (2011) c-MET: an exciting new target for anticancer therapy. Therapeutic Advances in Medical Oncology 3:1_suppl, pages S3-S5.
Crossref
Crossref
Shawna Leslie Organ & Ming-Sound Tsao. (2011) An overview of the c-MET signaling pathway. Therapeutic Advances in Medical Oncology 3:1_suppl, pages S7-S19.
Crossref
Crossref
Leen H. Kawas, Brent J. Yamamoto, John W. Wright & Joseph W. Harding. (2011) Mimics of the Dimerization Domain of Hepatocyte Growth Factor Exhibit Anti-Met and Anticancer Activity. Journal of Pharmacology and Experimental Therapeutics 339:2, pages 509-518.
Crossref
Crossref
Karen L. Milkiewicz, Lisa D. Aimone, Mark S. Albom, Thelma S. Angeles, Hong Chang, Jennifer V. Grobelny, Jean Husten, Christine LoSardo, Sheila Miknyoczki, Seetha Murthy, Damaris Rolon-Steele, Ted L. Underiner, Linda R. Weinberg, Candace S. Worrell, Kelli S. Zeigler & Bruce D. Dorsey. (2011) Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorganic & Medicinal Chemistry 19:21, pages 6274-6284.
Crossref
Crossref
Jason D. Katz, James P. Jewell, David J. Guerin, Jongwon Lim, Christopher J. Dinsmore, Sujal V. Deshmukh, Bo-Sheng Pan, C. Gary Marshall, Wei Lu, Michael D. Altman, William K. Dahlberg, Lenora Davis, Danielle Falcone, Ana E. Gabarda, Gaozhen Hang, Harold Hatch, Rachael Holmes, Kaiko Kunii, Kevin J. Lumb, Bart Lutterbach, Robert Mathvink, Naim Nazef, Sangita B. Patel, Xianlu Qu, John F. Reilly, Keith W. Rickert, Craig Rosenstein, Stephen M. Soisson, Kerrie B. Spencer, Alexander A. Szewczak, Deborah Walker, Wenxian Wang, Jonathan Young & Qinwen Zeng. (2011)
Discovery of a 5
H
-Benzo[4,5]cyclohepta[1,2-
b
]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer
. Journal of Medicinal Chemistry 54:12, pages 4092-4108.
Crossref
Crossref
Keila E. Torres, Quan-Sheng Zhu, Katelynn Bill, Gonzalo Lopez, Markus P. Ghadimi, Xianbiao Xie, Eric D. Young, Juehui Liu, Theresa Nguyen, Svetlana Bolshakov, Roman Belousov, Suizhau Wang, Guy Lahat, Jun Liu, Belinda Hernandez, Alexander J. Lazar & Dina Lev. (2011) Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors. Clinical Cancer Research 17:12, pages 3943-3955.
Crossref
Crossref
Yuanxiang Wang, Jing Ai, Ying Wang, Yi Chen, Lu Wang, Gang Liu, Meiyu Geng & Ao Zhang. (2011) Synthesis and c-Met Kinase Inhibition of 3,5-Disubstituted and 3,5,7-Trisubstituted Quinolines: Identification of 3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a Novel Anticancer Agent. Journal of Medicinal Chemistry 54:7, pages 2127-2142.
Crossref
Crossref
Julio Caballero, Miguel Quiliano, Jans H. Alzate-Morales, Mirko Zimic & Eric Deharo. (2011) Docking and quantitative structure–activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors. Journal of Computer-Aided Molecular Design 25:4, pages 349-369.
Crossref
Crossref
David Liska, Chin-Tung Chen, Thomas Bachleitner-Hofmann, James G. Christensen & Martin R. Weiser. (2011) HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation. Clinical Cancer Research 17:3, pages 472-482.
Crossref
Crossref
In-hae KwakYun-Hye ShinMyeongdeok KimHyun-Young ChaHyun-Ja NamBok-Soon LeeS.C. ChaudharyKi-Soo PaiJae-Ho Lee. (2011) Epigallocatechin-3-gallate inhibits paracrine and autocrine hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion. Experimental and Molecular Medicine 43:2, pages 111.
Crossref
Crossref
Donald J. AbrahamRobert H. Bradbury. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
295
344
.
Sharon Diamond, Jason Boer, Thomas P. MaduskuieJr.Jr., Nikoo Falahatpisheh, Yu Li & Swamy Yeleswaram. (2010) Species-Specific Metabolism of SGX523 by Aldehyde Oxidase and the Toxicological Implications. Drug Metabolism and Disposition 38:8, pages 1277-1285.
Crossref
Crossref
Bo-Sheng Pan, Grace K.Y. Chan, Melissa Chenard, An Chi, Lenora J. Davis, Sujal V. Deshmukh, Jackson B. Gibbs, Susana Gil, Gaozhen Hang, Harold Hatch, James P. Jewell, Ilona Kariv, Jason D. Katz, Kaiko Kunii, Wei Lu, Bart A. Lutterbach, Cloud P. Paweletz, Xianlu Qu, John F. Reilly, Alexander A. Szewczak, Qinwen Zeng, Nancy E. Kohl & Christopher J. Dinsmore. (2010) MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor. Cancer Research 70:4, pages 1524-1533.
Crossref
Crossref
Xiangdong Liu, Robert C. Newton & Peggy A. Scherle. (2010) Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends in Molecular Medicine 16:1, pages 37-45.
Crossref
Crossref
Wen-Sheng Wu & Chi-Tan Hu. 2010. Signal Transduction in Cancer Metastasis. Signal Transduction in Cancer Metastasis
9
24
.
Christopher Jedeszko, Bernadette C. Victor, Izabela Podgorski & Bonnie F. Sloane. (2009)
Fibroblast Hepatocyte Growth Factor Promotes Invasion of Human Mammary Ductal Carcinoma
In situ
. Cancer Research 69:23, pages 9148-9155.
Crossref
Crossref
Andrea L. Russo, Kimberly Jedlicka, Meredith Wernick, Debbie McNally, Melissa Kirk, Mary Sproull, Sharon Smith, Uma Shankavaram, Aradhana Kaushal, William D. Figg, William Dahut, Deborah Citrin, Donald P. Bottaro, Paul S. Albert, Philip J. Tofilon & Kevin Camphausen. (2009) Urine Analysis and Protein Networking Identify Met as a Marker of Metastatic Prostate Cancer. Clinical Cancer Research 15:13, pages 4292-4298.
Crossref
Crossref
Sergei L. Timofeevski, Michele A. McTigue, Kevin Ryan, Jean Cui, Helen Y. Zou, Jeff X. Zhu, Fannie Chau, Gordon Alton, Shannon Karlicek, James G. Christensen & Brion W. Murray. (2009) Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors. Biochemistry 48:23, pages 5339-5349.
Crossref
Crossref
Lynn M. Knowles, Laura P. Stabile, Ann Marie Egloff, Mary E. Rothstein, Sufi M. Thomas, Christopher T. Gubish, Edwina C. Lerner, Raja R. Seethala, Shinsuke Suzuki, Kelly M. Quesnelle, Sarah Morgan, Robert L. Ferris, Jennifer R. Grandis & Jill M. Siegfried. (2009) HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer. Clinical Cancer Research 15:11, pages 3740-3750.
Crossref
Crossref
Xiuqin Lou, Qibing Zhou, Ying Yin, Cheng Zhou & Yan Shen. (2009) Inhibition of the met receptor tyrosine kinase signaling enhances the chemosensitivity of glioma cell lines to CDDP through activation of p38 MAPK pathway. Molecular Cancer Therapeutics 8:5, pages 1126-1136.
Crossref
Crossref
Joseph Paul Eder, George F. Vande Woude, Scott A. Boerner & Patricia M. LoRusso. (2009) Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer. Clinical Cancer Research 15:7, pages 2207-2214.
Crossref
Crossref
Gretchen M. Schroeder, Yongmi An, Zhen-Wei Cai, Xiao-Tao Chen, Cheryl Clark, Lyndon A. M. Cornelius, Jun Dai, Johnni Gullo-Brown, Ashok Gupta, Benjamin Henley, John T. Hunt, Robert Jeyaseelan, Amrita Kamath, Kyoung Kim, Jonathan Lippy, Louis J. Lombardo, Veeraswamy Manne, Simone Oppenheimer, John S. Sack, Robert J. Schmidt, Guoxiang Shen, Kevin Stefanski, John S. Tokarski, George L. Trainor, Barri S. Wautlet, Donna Wei, David K. Williams, Yingru Zhang, Yueping Zhang, Joseph Fargnoli & Robert M. Borzilleri. (2009)
Discovery of
N
-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
. Journal of Medicinal Chemistry 52:5, pages 1251-1254.
Crossref
Crossref
Yi-Nong Niu & Shu-Jie Xia. (2008) Stroma–epithelium crosstalk in prostate cancer. Asian Journal of Andrology 11:1, pages 28-35.
Crossref
Crossref